# Treatment With Pyrotinib-Based Therapy in Lapatinib Resistant HER2-Positive Metastatic Breast Cancer

> **NCT04899128** · — · UNKNOWN · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 100 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Pyrotinib

## Key facts

- **NCT ID:** NCT04899128
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-08-01
- **Primary completion:** 2020-08-01
- **Final completion:** 2021-06
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2021-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04899128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04899128, "Treatment With Pyrotinib-Based Therapy in Lapatinib Resistant HER2-Positive Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04899128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*